Response of a co-culture model of epithelial cells and gingival fibroblasts to zoledronic acid
Abstract Osteonecrosis of the jaw is an adverse effect of bisphosphonates. While the etiopathogenesis of this condition has been investigated, the interactions and effects of bisphosphonates on oral mucosa cells remain unclear. It is hypothesized that cell culture models, such as co-culture or three-dimensional cell culture models, can provide valuable insight. Therefore, the aim of this study was to evaluate the effects of zoledronic acid (ZA) on epithelial cells and gingival fibroblasts in a co-culture model. Briefly, epithelial cells were seeded on transwell inserts and gingival fibroblasts were seeded in the lower well...
Source: Brazilian Oral Research - November 29, 2016 Category: Dentistry Source Type: research

SEOM Clinical Guideline for bone metastases from solid tumours (2016)
AbstractBone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compression, need of bone irradiation or need of bone surgery, and hypercalcaemia. Patients with bone metastases experience pain, functional impairment and have a negative impact on their quality of life. Several imaging techniques are available for diagnosis of this disease. Bone-targeted therapies include zoledronic acid, a potent biphosfonate, and denosumab, an anti-RANKL mon...
Source: Clinical and Translational Oncology - November 28, 2016 Category: Cancer & Oncology Source Type: research

Zoledronic acid overcomes adriamycin resistance in acute myeloid leukemia cells by promoting apoptosis.
Authors: Fan RF, Chen YX, Fang ZG, Guo XY, Lu Y, Liu LL, Xu YC, Liu XF, Lin DJ Abstract Zoledronic acid (ZOL), a nitrogen‑containing bisphosphonate, is widely used in metastatic bone disease. Previous studies indicate that ZOL has marked anti‑leukemia activity, however, the underlying mechanism of action remains to be elucidated. The present study aimed to explore the mechanism of the anti‑leukemia effect of ZOL in leukemia cells. It was observed that ZOL inhibited the proliferation of HL‑60 and adriamycin‑resistant HL‑60 (HL‑60/A) cells using a WST‑8 assay. An Annexin V‑propidium iodide indicated...
Source: Molecular Medicine Reports - November 25, 2016 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Immune modulation of CD4+CD25+ regulatory T cells by zoledronic acid
CD4+CD25+ regulatory T (Treg) cells suppress tumor immunity by inhibiting immune cells. Manipulation of Treg cells represents a new strategy for cancer treatment. Zoledronic acid (ZA), a nitrogen-containing bisph... (Source: BMC Immunology)
Source: BMC Immunology - November 25, 2016 Category: Allergy & Immunology Authors: Hsien Liu, Shih-Han Wang, Shin-Cheh Chen, Ching-Ying Chen, Jo-Lin Lo and Tsun-Mei Lin Source Type: research

Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis
ConclusionsZA infusion did not affect P wave dispersion both at the immediate post-infusion period and 1  month after infusion. QT values were significantly increased early after ZA infusion; however, there were no significant differences in parameters reflecting disparity of ventricular recovery times and transmural dispersion of ventricular repolarization. Based on these observations, it may be sugg ested that ZA infusion did not have any short- or long-term effect on any parameter that might be associated with the tendency for atrial fibrillation or ventricular arrhythmias. (Source: Osteoporosis International)
Source: Osteoporosis International - November 23, 2016 Category: Orthopaedics Source Type: research

Osteoporosis in Pediatric Liver Transplantation
We present a case of a 13-year-old female patient who underwent an orthotopic liver transplant for cryptogenic liver cirrhosis. Her immunosuppressants were tacrolimus and prednisone. Four months posttransplant, she started complaining of bilateral lower limb pain and limping while walking, progressing to a point where she was almost immobile. Magnetic resonance imagining of the pelvis showed bilateral avascular necrosis involving the weight-bearing surfaces of both femoral heads, in addition to the extensive edema involving both hip joints. Bone mineral densitometry was below normal for her age at the hip and forearm. She ...
Source: Progress in Transplantation - November 21, 2016 Category: Transplant Surgery Authors: Faraj, W., El Nounou, G., Abou Al Naaj, A., Nakhoul, N., Haydar, A., Khalife, M. Tags: Case Reports Source Type: research

Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates
AbstractThe aim of the study is to report the rare association of two complications of long-term treatment of osteoporosis with bisphosphonates in the same Caucasian elderly patient. A female patient of Italian descent, age 87  years, consulted in February 2013. She had a history of osteoporosis and had taken alendronate weekly for 7 years (1999–2006). Due to low back pain, an orthopedist had indicated i.v. zoledronic acid, 5 mg/year for 3 years (2006–2008). She received occasional supplements of ergocalciferol. I n 2009, she suffered a fall and sustained a subtrochanteric fracture of the le...
Source: Osteoporosis International - November 20, 2016 Category: Orthopaedics Source Type: research

Zoledronic Acid (Reclast ® , Aclasta ® ): A Review in Osteoporosis
AbstractZoledronic acid (Reclast®, Aclasta®) is an intravenous, highly potent aminobisphosphonate approved worldwide, including in the USA, EU and Japan for use in patients with primary or secondary osteoporosis or low bone mass (approved indications vary between countries). Its high affinity to and long half-life in bone, and long duration of action, allow for once-yearly administration, which has the potential to improve adherence to therapy. Zoledronic acid once yearly for up to 3  years improved bone mineral density (BMD) at several skeletal sites, reduced fracture risk and bone turnover, and/or preserved ...
Source: Drugs - November 18, 2016 Category: Drugs & Pharmacology Source Type: research

P2-274 * PII trial of zoledronic acid in NSCLC pts with bone metastases and elevated marker of osteoclast activity
(Source: Annals of Oncology)
Source: Annals of Oncology - November 17, 2016 Category: Cancer & Oncology Authors: Fukuda, M., Kitazaki, T., Harada, T., Suetsugu, T., Kawasaki, M., Wataya, H., Furugen, M., Tokunaga, S., Takayama, K., Sugio, K. Tags: PII trial of zoledronic acid in NSCLC pts with bone metastases and elevated marker of osteoclast activity Source Type: research

Adoptive transfer of ex vivo expanded v γ9vδ2 t cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer
In this study, ex vivo expanded cytotoxic V γ9Vδ2 T cells isolated from human peripheral blood were tested for their anti-cancer efficacy in combination with zoledronic acid (ZOL), using a mouse model of osteolytic breast cancer. In vitro, expanded Vγ9Vδ2 T cells were cytotoxic against a panel of human breast cancer cell lines, and ZOL pr e-treatment further sensitised breast cancer cells to killing by Vγ9Vδ2 T cells. (Source: Cancer Letters)
Source: Cancer Letters - November 16, 2016 Category: Cancer & Oncology Authors: Aneta Zysk, Mark O. DeNichilo, Vasilios Panagopoulos, Irene Zinonos, Vasilios Liapis, Shelley Hay, Wendy Ingman, Vladimir Ponomarev, Gerald Atkins, David Findlay, Andrew Zannettino, Andreas Evdokiou Source Type: research

Adoptive transfer of ex  vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer
In this study, ex  vivo expanded cytotoxic Vγ9Vδ2 T cells isolated from human peripheral blood were tested for their anti-cancer efficacy in combination with zoledronic acid (ZOL), using a mouse model of osteolytic breast cancer. In vitro, expanded Vγ9Vδ2 T cells were cytotoxic against a panel of human breast c ancer cell lines, and ZOL pre-treatment further sensitised breast cancer cells to killing by Vγ9Vδ2 T cells. (Source: Cancer Letters)
Source: Cancer Letters - November 16, 2016 Category: Cancer & Oncology Authors: Aneta Zysk, Mark O. DeNichilo, Vasilios Panagopoulos, Irene Zinonos, Vasilios Liapis, Shelley Hay, Wendy Ingman, Vladimir Ponomarev, Gerald Atkins, David Findlay, Andrew Zannettino, Andreas Evdokiou Tags: Original Article Source Type: research

21 The efficacy of zoledronic acid for the prevention of bone metastases in patients with renal cell cancer
Publication date: December 2016 Source:European Urology Supplements, Volume 15, Issue 11 Author(s): S. Boychuk, A. Dedkov, I. Vitruk, O. Voilenko, E. Stakhovsky (Source: European Urology Supplements)
Source: European Urology Supplements - November 15, 2016 Category: Urology & Nephrology Source Type: research

Expansion of Th1-like V γ9Vδ2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid
Expansion of Th1-like Vγ9Vδ2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid Leukemia advance online publication, November 4 2016. doi:10.1038/leu.2016.273 Authors: T Harada, H Miki, Q Cui, A Oda, R Amachi, J Teramachi, A Bat-Erdene, K Sogabe, M Iwasa, S Fujii, S Nakamura, K Kagawa, S Yoshida, I Endo, K Aihara, S Ozaki, T Matsumoto & M Abe (Source: Leukemia)
Source: Leukemia - November 4, 2016 Category: Hematology Authors: T Harada H Miki Q Cui A Oda R Amachi J Teramachi A Bat-Erdene K Sogabe M Iwasa S Fujii S Nakamura K Kagawa S Yoshida I Endo K Aihara S Ozaki T Matsumoto M Abe Source Type: research

Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231
Conclusion: ZOL reduces the motility and cellular velocity of breast cancer cells in vitro. The reduced mobility might slow down or even stop metastasis, which is a known result of adjuvant ZOL therapy in breast cancer patients. In vivo studies are warranted to evaluate the impact of the reduced motility on the metastatic cascade. (Source: In Vivo)
Source: In Vivo - November 4, 2016 Category: Research Authors: BUHLER, H., HOBERG, C., FAKHRIAN, K., ADAMIETZ, I. A. Tags: Experimental Studies Source Type: research

Zoledronic acid
(Source: Reactions Weekly)
Source: Reactions Weekly - November 1, 2016 Category: Drugs & Pharmacology Source Type: research

Intravenous Zoledronic Acid 5  mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24‐month Clinical Study
ObjectiveThis randomized, double‐blind, placebo‐controlled study assessed the necessity of early intervention, safety and efficacy of intravenous zoledronic acid 5 mg/year in East China women with newly diagnosed osteoporosis at high risk of fracture during a 24‐month treatment period. MethodsSubjects (57 [52–62] years old) were randomized 3:2 to zoledronic acid versus placebo (randomized at baseline, zoledronic acid [175 cases], placebo‐zoledronic acid [110 cases]). The bone mineral density of the lumbar spine and total hip was measured every 6 months with the use of dual‐energy X‐ray absor...
Source: Orthopaedic Surgery - November 1, 2016 Category: Orthopaedics Authors: Bo ‐cheng Liang, Zhen‐yu Shi, Bo Wang, Peng Wu, Ling‐cheng Kong, Jian‐liang Yao, Chun‐wen Li, Xiao‐lin Shi Tags: CLINICAL ARTICLE Source Type: research

Effect of a local, one time, low-dose injection of zoledronic acid on titanium implant osseointegration in ovariectomized rats.
CONCLUSIONS: A local, one time, low-dose injection of ZOL at the site of implantation is able to promote the osseointegration of Ti implants following postmenopausal osteoporosis, and this action may be partly mediated by inhibition of the osteoporosis-induced AGE overproduction in the bone marrow. PMID: 27695483 [PubMed - in process] (Source: Archives of Medical Science)
Source: Archives of Medical Science - October 4, 2016 Category: Journals (General) Tags: Arch Med Sci Source Type: research

PTH(1 –34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology
This study aimed to characterize longitudinal effects of representative anabolic (parathyroid hormone, PTH) and anti‐catabolic (zoledronic acid, ZA) drugs on skeletal morphology, mechanical strength, and growth in juvenile mice. BALB/cJ mice aged 4 weeks were given PTH(1–34) or vehicle (control) daily for 8 weeks, or 4 weekly doses of ZA, and evaluated at time points 0–26 weeks after treatment initiation. There were no enduring differences in body length or mass between treatment groups. ZA increased femur size as early as week 0, including increased distal femur bone volume and diaphyseal cross‐sectional a...
Source: Journal of Orthopaedic Research - October 3, 2016 Category: Orthopaedics Authors: Christopher M. Bartlow, Megan E. Oest, Kenneth A. Mann, Nicholas D. Zimmerman, Bilal B. Butt, Timothy A. Damron Tags: Research Article Source Type: research

Current therapeutic options targeting bone metastasis in metastatic castration resistant prostate cancer.
Authors: Fragkoulis C, Gkialas I, Papadopoulos G, Ntoumas K Abstract Prostate cancer is a major public health problem worldwide, still remaining the most common cancer among elder males in both Europe and USA, being responsible for approximately 30,000 deaths in USA in 2014. Nowadays, after decades of basic research, novel treatment options have emerged focusing on men suffering from metastatic castration-resistant prostate cancer improving overall survival. It is also estimated that more than 90% of such patients develop bone metastasis, resulting in a significant increase in morbidity and mortality. The purpose o...
Source: Journal of B.U.ON. - October 1, 2016 Category: Cancer & Oncology Tags: J BUON Source Type: research

Bone ‐site‐specific responses to zoledronic acid
ConclusionsOur findings provide more insight into bone‐site‐specific effects of bisphosphonates and into the aetiology of osteonecrosis of the jaw. We demonstrated that bisphosphonates can stimulate osteoclast activity at the molar roots.This article is protected by copyright. All rights reserved. (Source: Oral Diseases)
Source: Oral Diseases - October 1, 2016 Category: ENT & OMF Authors: Jenny A.F. Vermeer, Greetje A.P. Renders, Marion A. van Duin, Ineke D.C. Jansen, Lieneke F. Bakker, Sophie A. Kroon, Teun J. de Vries, Vincent Everts Tags: Original Article Source Type: research

Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid
Abstract Background and AimsWe retrospectively analyzed the clinical outcome and prognostic parameters in patients with hepatocellular carcinoma (HCC) and bone metastases who had received treatment with zoledronic acid. MethodsNinety‐nine HCC patients with bone metastases who had been treated with zoledronic acid (ZOL) were enrolled in this retrospective cohort study. We analyzed the prognostic factors, including serum N‐telopeptide of type I collagen (NTX) levels as the bone metabolism marker. ResultsThe median overall survival time was 11.5 months. Child‐Pugh grade A (P = 0.004) and intrahepati...
Source: Hepatology Research - October 1, 2016 Category: Internal Medicine Authors: Yohji Honda, Hiroshi Aikata, Fumi Honda, Norihito Nakano, Yuki Nakamura, Masahiro Hatooka, Kei Morio, Tomoki Kobayashi, Takayuki Fukuhara, Yuko Nagaoki, Tomokazu Kawaoka, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Kazuaki Chayama Tags: Original Article Source Type: research

Persistence with denosumab and zoledronic acid among older women: a population-based cohort study
ConclusionThe persistence rate to denosumab and zoledronic acid was higher to the published data of oral bisphosphonates. The second intention of treatment seems to target more severe patients which may more likely to be compliant. (Source: Archives of Osteoporosis)
Source: Archives of Osteoporosis - September 27, 2016 Category: Orthopaedics Source Type: research

Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor
. (Source: OncoImmunology)
Source: OncoImmunology - September 27, 2016 Category: Cancer & Oncology Authors: A. Bertaina A. Zorzoli A. Petretto G. Barbarito E. Inglese P. Merli C. Lavarello L. P. Brescia B. De Angelis G. Tripodi L. Moretta F. Locatelli I. Airoldi Source Type: research

Orbital Inflammation Secondary to Zoledronic Acid, a Rare Presentation
No abstract available (Source: JCR: Journal of Clinical Rheumatology)
Source: JCR: Journal of Clinical Rheumatology - September 24, 2016 Category: Rheumatology Tags: Images Source Type: research

Osteogenesis imperfecta type V: Genetic and clinical findings in eleven Chinese patients.
Abstract INTRODUCTION: Osteogenesis imperfecta (OI) type V is a rare inherited disease characterized by multiple fractures, intraosseous membrane calcification, and hypercallus formation. We investigate the causative gene, phenotype and also observe the effects of zoledronic acid in Chinese OI type V patients. METHODS: The clinical phenotype and causative gene mutation was investigated in eleven patients with type V OI. Patients were given a dose of zoledronic acid 5mg intravenously. Fracture incidence and Z-score of bone mineral density (BMD) were evaluated. Serum levels of biomarkers such as cross linked C-...
Source: International Journal of Clinical Chemistry - September 24, 2016 Category: Chemistry Authors: Liu Y, Wang J, Ma D, Lv F, Xu X, Xia W, Jiang Y, Wang O, Xing X, Zhou P, Wang J, Yu W, ASAN, Li M Tags: Clin Chim Acta Source Type: research

PTH(1 ‐34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology
This study aimed to characterize longitudinal effects of representative anabolic (parathyroid hormone, PTH) and anti‐catabolic (zoledronic acid, ZA) drugs on skeletal morphology, mechanical strength, and growth in juvenile mice. BALB/cJ mice aged four weeks were given PTH(1–34) or vehicle (control) daily for eight weeks, or four weekly doses of ZA, and evaluated at time points 0–26 weeks after treatment initiation. There were no enduring differences in body length or mass between treatment groups. ZA increased femur size as early as week 0, including increased distal femur bone volume and diaphyseal cross‐s...
Source: Journal of Orthopaedic Research - September 21, 2016 Category: Orthopaedics Authors: Christopher M. Bartlow, Megan E. Oest, Kenneth A. Mann, Nicholas D. Zimmerman, Bilal B. Butt, Timothy A. Damron Tags: Research Article Source Type: research

Zoledronic Acid Treatment After Acute Spinal Cord Injury: Results  of a Randomized, Placebo-Controlled Pilot Trial
Conclusions Zoledronic acid is effective at mitigating bone loss after SCI. Duration of efficacy and activity at different skeletal sites may differ from that observed in able-bodied individuals and needs further study. (Source: PMandR)
Source: PMandR - September 18, 2016 Category: Rehabilitation Source Type: research

A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial
AbstractObjectiveTo examine the antitumor activity of zoledronic acid (ZA) combined with androgen deprivation therapy (ADT) for men with treatment-naive prostate cancer and bone metastasis.MethodsWe enrolled 227 men with treatment-naive prostate cancer and bone metastasis. Participants were randomly assigned (1:1 ratio) to receive combined androgen blockade alone (CAB group) or ZA with combined androgen blockade (CZ group). Time to treatment failure (TTTF), time to the first skeletal-related event (TTfSRE), and overall survival (OS) rates were estimated using the Kaplan –Meier method. Hazard ratios (HRs) were calcula...
Source: International Journal of Clinical Oncology - September 10, 2016 Category: Cancer & Oncology Source Type: research

Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
AbstractSummaryIn a 2-year randomized, placebo-controlled study of 665 Japanese patients with primary osteoporosis, once-yearly administration of zoledronic acid (5  mg) reduced the risk of new morphometric vertebral fractures.IntroductionThe purpose of this study was to determine the efficacy and safety of once-yearly intravenous infusion of ZOL in Japanese patients with primary osteoporosis.MethodsThis was a two-year multicenter, randomized, placebo-controlled, double-blind, parallel-group comparative study (ZONE Study). Subjects were 665 Japanese patients between the ages of 65 and 89  years who had prevalent ...
Source: Osteoporosis International - September 8, 2016 Category: Orthopaedics Source Type: research

[Corrigendum] Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines.
Abstract Following the publication of the above article, an interested reader drew an anomaly associated with the presentation of Fig. 7 to our attention. Essentially, the panel showing the Cis 0.001 data at T0 for the BRC-230 cell line was the same as that showing the Cis 0.01 data. After having re-examined our data, we realized that an error must have occurred when preparing Fig. 7. A duplication of the photo corresponding to BRC-230 Cis 0.001 T0 was incorrectly placed in the position corresponding to BRC-230 Cis 0.01 T0, while the correct BRC-230 Cis 0.01 T0 figure was erroneously positioned in t...
Source: International Journal of Oncology - September 1, 2016 Category: Cancer & Oncology Authors: Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D Tags: Int J Oncol Source Type: research

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Conclusions The knowledge in the field of advanced and metastatic PCa and CRPC is changing rapidly. The 2016 EAU-ESTRO-SIOG Guidelines on PCa summarise the most recent findings and advice for use in clinical practice. These PCa guidelines are the first endorsed by the European Society for Therapeutic Radiology and Oncology and the International Society of Geriatric Oncology and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office or online (http://uroweb.org/guideline/prostate-cancer/). Patient summary In men with a rise in their PSA levels after prior local treatment for ...
Source: European Urology - September 1, 2016 Category: Urology & Nephrology Source Type: research

Effects of Zoledronic Acid on Orthodontic Tooth Movement in Rats.
Abstract The purpose of this study was to assess the effects of the administration of zoledronic acid (ZA) during orthodontic movement in rats. A hundred and twenty male Wistar rats were applied force of 30 cN with spring closed nickel-titanium to move the upper right first molar to mesial. In the Control Movement group (CM), only tooth movement was performed; the Control Acid Zoledronic group (CAZ) received a single dose (0.1 mg/kg) of ZA; the Experimental Acid Zoledronic group (EAZ) received a single dose (0.1 mg/kg) one week prior to the start of tooth movement; and the Control Without movement group (CWM) that...
Source: Braz Dent J - September 1, 2016 Category: Dentistry Authors: Brunet MD, Araujo CM, Johann AC, Camargo ES, Tanaka OM, Guariza O Tags: Braz Dent J Source Type: research

Breast cancer and bone metastases: a call for appropriate treatment
ConclusionsAdoption of a number of behavioral changes may help to overcome barriers to earlier initiation of treatment with bone-targeted agents in these patients. This includes raising awareness of the guidelines that are available for bone-targeted therapies, providing physician and patient education on the appropriate use of these agents, and highlighting to physicians the importance of early treatment and regular monitoring for adverse events. Earlier initiation of treatment should help to reduce the risk of SREs and thus lessen the burden that these debilitating skeletal complications place on patients and healthcare ...
Source: Supportive Care in Cancer - August 23, 2016 Category: Cancer & Oncology Source Type: research

Osteoblast-like cells with different embryological origins behave differently to increasing zoledronic acid concentrations - A pilot study in pigs
We compared the intra-individual effects of increasing zoledronic acid (ZA) concentrations on osteoblast-like cells with different embryological origins. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - August 18, 2016 Category: ENT & OMF Authors: Philipp Kauffmann, Wolfram Hahn, Niklas Sievers, Markus Troeltzsch, Karin Hohloch, Phillipp Brockmeyer, Robert Cordesmeyer, Henning Schliephake, Rudolf Matthias Gruber Source Type: research

Osteoblast-like cells with different embryological origins behave differently to increasing zoledronic acid concentrations - A pilot study in pigs
Conclusion Cultured mandibular osteoblast-like cells reacted more sensitively to high ZA concentrations than osteoblast-like cells from the iliac crest. (Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology)
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - August 18, 2016 Category: ENT & OMF Source Type: research

Osteoblast-like cells with different embryologic origins behave differently in increasing zoledronic acid concentrations: a pilot study in pigs
We compared the intraindividual effects of increasing zoledronic acid (ZA) concentrations on osteoblast-like cells with different embryologic origins. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - August 18, 2016 Category: ENT & OMF Authors: Philipp Kauffmann, Wolfram Hahn, Niklas Sievers, Markus Troeltzsch, Karin Hohloch, Phillipp Brockmeyer, Robert Cordesmeyer, Henning Schliephake, Rudolf Matthias Gruber Tags: Original article Source Type: research

N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
CONCLUSION: In the present contemporaneous cohort of BC patients with BMs, the NTX response at 3 months was strongly associated with survival. Furthermore, an early response to ZA was strongly associated with long-term NTX control. Finally, patients with BMs plus extraskeletal metastases had an erratic NTX variation. IMPLICATIONS FOR PRACTICE: The present study showed that when accommodating recent therapy innovations and longer patient survival, the N-telopeptide (NTX) variation at 3 months is strongly associated with survival. In this setting, in addition to a few other clinicopathological features, NTX is a powerfu...
Source: The Oncologist - August 17, 2016 Category: Cancer & Oncology Authors: Ferreira AR, Alho I, Shan N, Matias M, Faria M, Casimiro S, Leitzel K, Ali S, Lipton A, Costa L Tags: Oncologist Source Type: research

Effect of combined treatment with zoledronic acid and parathyroid hormone on mouse bone callus structure and composition
In recent years, great interest in combined treatment of parathyroid hormone (PTH) with anti-resorptive therapy has emerged. PTH has been suggested to aid bridging of atrophic fractures and improve strength in closed fracture models. Bisphosphonate treatments typically result in a larger woven bone callus that is slower to remodel. The combination of both drugs has been demonstrated to be effective for the treatment of osteoporotic bone loss in many preclinical studies. However, the effect of combined treatment on fracture repair is still largely unexplored. (Source: Bone)
Source: Bone - August 16, 2016 Category: Orthopaedics Authors: Michele Casanova, Janelle Herelle, Marcel Thomas, Rowan Softley, Aaron Schindeler, David Little, Philipp Schneider, Ralph M üller Source Type: research

A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial
Background. Human immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) are associated with bone loss leading to increased fracture rate among HIV-infected individuals. ART-induced bone loss is most intense within the first 48 weeks of therapy, providing a window for prophylaxis with long-acting antiresorptives. Methods. In a phase 2, double-blind, placebo-controlled trial, we randomized 63 nonosteoporotic, ART-naive adults with HIV initiating ART with atazanavir/ritonavir + tenofovir/emtricitabine to a single zoledronic acid (ZOL) infusion (5 mg) vs placebo to determine the efficacy of ZOL in m...
Source: Clinical Infectious Diseases - August 12, 2016 Category: Infectious Diseases Authors: Ofotokun, I., Titanji, K., Lahiri, C. D., Vunnava, A., Foster, A., Sanford, S. E., Sheth, A. N., Lennox, J. L., Knezevic, A., Ward, L., Easley, K. A., Powers, P., Weitzmann, M. N. Tags: HIV/AIDS Source Type: research

Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease
We present the results of these studies as well as a brief overview of TAO including presentation, pathogenesis, and management. Most of the studies identified are of poor quality, are not random ized controlled, and include small number of participants. There are no data concerning effects on fracture rates. Bisphosphonates are the most widely studied agents and among them zoledronic acid is the most well studied. Hormone replacement treatment (HRT) shows beneficial but small effects. Denos umab and strontium ranelate have each been evaluated in only a single study, while there are no data about the effects of anabolic ag...
Source: Osteoporosis International - August 8, 2016 Category: Orthopaedics Source Type: research

Prevention and management of osteonecrosis of the jaw secondary to bone-targeted therapy in patients with kidney cancer
Purpose of review: The aim of this revision is prevention and management of osteonecrosis of the jaw (ONJ) secondary to bone-targeted therapy in patients with kidney cancer. Recent findings: Patients with kidney cancer treated with zoledronate suffered from ONJ earlier compared with patients with breast cancer or multiple myeloma; among men, ONJ occurred at 24 months of zoledronic acid treatment in more than 80% of the patients and much earlier, in respect to patients with prostate cancer or multiple myeloma. Protective factors against an ONJ can be sequential prescription of different bisphosphonates and female sex. Less...
Source: Current Opinion in Supportive and Palliative Care - August 5, 2016 Category: Palliative Care Tags: RENAL AND UROLOGICAL PROBLEMS: Edited by Fred Saad Source Type: research

Prevention of Bisphosphonate-Related Osteonecrosis of the Jaws in Patients with Prostate Cancer Treated with Zoledronic acid – a prospective study over 6 years
Conclusions Preventive oral and maxillofacial treatment before bisphosphonate application combined with 3-monthly dental follow-ups significantly reduces the occurrence and risk of BRONJ in PC patients. Therefore this approach should be implemented in the specific treatment algorithms. (Source: Journal of Cranio Maxillofacial Surgery)
Source: Journal of Cranio Maxillofacial Surgery - August 3, 2016 Category: ENT & OMF Source Type: research

Prevention of Bisphosphonate-Related Osteonecrosis of the Jaws in Patients with Prostate Cancer Treated with Zoledronic acid – a prospective study over 6 years
To explore the preventive effect of a prophylactic oral and maxillofacial treatment to reduce bisphosphonate associated necrosis of the jaws (BRONJ) in metastatic prostate cancer (PC) patients treated with zoledronic acid (4.0 mg i.v./months). (Source: Journal of Cranio-Maxillofacial Surgery)
Source: Journal of Cranio-Maxillofacial Surgery - August 1, 2016 Category: ENT & OMF Authors: Thomas M ücke, Herbert Deppe, Jana Hein, Klaus-Dietrich Wolff, David A. Mitchell, Marco R. Kesting, Margitta Retz, Jürgen E. Gschwend, Mark Thalgott Source Type: research

Sorafenib/zoledronic acid
(Source: Reactions Weekly)
Source: Reactions Weekly - August 1, 2016 Category: Drugs & Pharmacology Source Type: research

Severe Compromise of Preosteoblasts in a Surgical Mouse Model of Bisphosphonate-Associated Osteonecrosis of the Jaw
Conclusion The severe imbalance between bone-forming cells and bone-resorbing cells shown in this study could contribute to the pathogenesis of BONJ. (Source: Journal of Cranio Maxillofacial Surgery)
Source: Journal of Cranio Maxillofacial Surgery - July 27, 2016 Category: ENT & OMF Source Type: research

Combinatorial effect of zoledronic acid and irradiation on the prevention of DMBA-induced precancerogenic changes in the mammary tissues of rats
Conclusions: The combination of RT and ZOL was more effective than either agent alone. Our results suggest that the administration of ZOL and irradiation in combination can offer maximal protection against DMBA-induced mammary precancerogenic changes. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - July 25, 2016 Category: Cancer & Oncology Authors: Simay G ü rocak Aysun Bay Karabulut Mehmet Tuzcu Nurhan & #350;ahin & #214;ztun Temelli Volkan & #304;nce Kazim & #350;ahin Source Type: research

Severe Compromise of Preosteoblasts in a Surgical Mouse Model of Bisphosphonate-Associated Osteonecrosis of the Jaw
The effect of amino-bisphosphonates on osteoblastic lineage and its potential contribution to the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw (BONJ) remain controversial. We assessed the effects of zoledronic acid (ZOL) on bone and vascular cells of the alveolar socket using a mouse model of BONJ. (Source: Journal of Cranio-Maxillofacial Surgery)
Source: Journal of Cranio-Maxillofacial Surgery - July 21, 2016 Category: ENT & OMF Authors: Luis A. C órdova, Florian Guilbaud, Jérôme Amiaud, Séverine Battaglia, Céline Charrier, Frédéric Lezot, Benoît Piot, Françoise Redini, Dominique Heymann Source Type: research

TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer, Health Technology Assessment, Vol:20, Iss:53
Authors: James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Russell M, Billingham L. (Source: NIHR Journals Library)
Source: NIHR Journals Library - July 19, 2016 Category: Global & Universal Source Type: research